An interventional study of Protégé and Protégé NC and Agent in Coronary Artery Disease, Drug Eluting Balloon and Drug Eluting Stent, sponsored by Translumina GmbH. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Translumina GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 34th largest by planned enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2026, is one of 78 with no phase, reaches primary completion later than 22 of the 40 other live ones, and was the 170th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Switzerland, Germany
Ages 18+
IGLESIAS Juan Fernando · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
ECRI bv · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 17 · Phase 4 25
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,380 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 296 across the 125 interventional studies, 992 across the 52 observational. Of the 114 that completed or were terminated, 25 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 177 have an industry lead sponsor. The 10 most frequent:
Translumina GmbH is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Translumina GmbH has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Artery Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04988685Luzerner KantonsspitalSIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters | 2026-12-31 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06706323Roland von KänelDepressive Symptoms After Cardiac Surgery | 2027-04-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two different paclitaxel-coated balloons, Protégé and Agent, with each other.
PCI with DES remains a cornerstone of interventional cardiology for the treatment of coronary artery disease. While DES have significantly improved outcomes compared to plain old angioplasty (POBA) and metal stents, there is still a risk of in-stent restenosis (ISR) and stent thrombosis (ST). To overcome these problems, non-stent techniques using only DCBs have emerged as a way of delivering anti-proliferative drugs to the vessel wall without the need for a permanent implant. It is hypothesised that this approach may promote positive remodelling and reduce the risk of vessel thrombosis and restenosis.
The use of PCI with DCB alone was first investigated for the treatment of ISR, where it showed good results and is currently recommended in guidelines for the treatment of ISR. There have also been several DCB trials in de novo coronary lesions, but the results have been more mixed. Many DCBs are now commercially available, both with paclitaxel and sirolimus coating, and it appears that there is no "class effect" due to the heterogeneity that exists within balloon designs, polymer coating, type of drug and concentrations used.
One of the first trials in de novo lesions, the PICCOLETO trial, was stopped early due to a higher MACE rate in the DCB group compared to the DES group. However, several weaknesses of the study may explain the worse outcome in those treated with DCBs compared to DES. The most important was probably the low dose of paclitaxel delivered by the balloon and the fact that only a small percentage of the population underwent lesion predilatation. Several studies have later shown non-inferiority of DCB to DES for de novo lesions, and the method is currently embraced by the interventional cardiology community.
Several DCBs are now available and approved for use, and more are on the way, but head-to-head data are scarce. The SPARX trial is designed to compare two DCBs, Protégé™ and Agent™, with conventional DES PCI in complex and small coronary lesions, with the idea that this type of coronary disease may benefit from a DCB-only technique. The trial will also compare the two certified and well-established paclitaxel-coated balloons, Protégé™ and Agent™. The hypothesis is that Protégé™ will perform at least as well as Agent™.
The primary objective of the SPARX trial is to compare paclitaxel-coated balloons with contemporary DES in complex and small coronary artery lesions in patients with non-ST elevation acute coronary syndrome (NSTEACS) or chronic coronary syndrome (CCS); The co-primary objective is to compare 2 different paclitaxel-coated balloons, Protégé™ and Agent™, with each other.
Clinical inclusion criteria:
of > 2 years
Angiographic inclusion criteria:
One or more trial target vessel (LAD, CX or RCA, or of their branches) with:
The target vessel/target lesion matches at least one of the following criteria
Lesion preparation must be according to the 3rd DCB consensus, with lesions that have:
Clinical exclusion criteria:
Participation in another investigation with an drug or another MD within the 30 days preceding and during the present investigation
Angiographic exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects Protege on the opted platform, then the patient is enrolled in this arm of the RCT
Device: Protégé and Protégé NC
Patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects Agent on the opted platform, then the patient is enrolled in this arm of the RCT
Device: Agent
DES to standard of care treatment during percutaneous coronary intervention. In this RCT, patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects DES (CE/FDA marked) on the opted platform, then the patient is enrolled in this arm of the RCT
Device: Drug Eluting Stent
Protégé Drug-eluting PTCA Balloon Catheters are rapid exchange catheters with a semi-compliant (Protégé DEB) balloon, or a non-compliant (NC) balloon (Protégé NC DEB), both with paclitaxel coating. Protégé is certified and CE marked.
The AgentTM Paclitaxel-Coated Balloon Catheter (AgentTM DCB) is a monorail, semi-compliant PCI catheter. Agent™ PCB is CE and FDA certified and approved for clinical use both in Europe and in the US.
Drug Eluting stents is a standard of care treatment for narrowed coronary arteries of the patients
Device oriented composite endpoint (DOCE)
1. Cardiac death 2. New target vessel - related myocardial infarction (TV-MI) 3. Ischemia-driven target-lesion revascularization (TLR)
Time frame: 24 months
Patient oriented composite endpoint (POCE)
1. All-cause death 2. Any Stroke 3. All new MI (TV and non-TV related) 4. Unplanned ischemia-driven repeat revascularization
Time frame: 1 month, 6 month, 12 month, 18 month, 24 month
Additional outcomes
Total no of events in 1380 patients will be analysed- 1. Definite or probable vessel (stent) thrombosis 2. Ischemia-driven target-vessel revascularization (TVR) 3. Major bleeding (BARC type 3 to 5)
Time frame: 1 month, 6 month, 12 month, 18 month, 24 months
All individual components of DOCE and POCE
Total no of events in 1380 patients will be analysed - 1. All-cause death 2. Cardiac death 3. Any Stroke 4. All new MI (TV and non-TV related) 5. Ischemia-driven TLR 6. Unplanned ischemia-driven repeat revascularization
Time frame: 1 month, 6 month, 12 month, 18 month, 24 month
Other outcomes of interest
Device success: Defined as the ability of the study devices to be delivered, dilated and retrieved from the target lesion during index procedure.
Time frame: 0 day (during index PCI)
Other outcomes of interest
Procedure duration, radiation exposure and contrast volume.
Time frame: 0 day (during index PCI)
Other outcomes of interest
Procedural success: Achievement of a final diameter stenosis of \< 30% (site-reported) using any PCI method, without the occurrence of death, MI or repeat vessel revascularization during index- hospital stay.
Time frame: 7 days
Other outcomes of interest
Acute or subacute vessel closure/thrombosis: diameter stenosis of 100% and/or TIMI flow grade 0.
Time frame: 7 days
Other outcomes of interest
Periprocedural myocardial injury within 48 hours (according to SCAI definition): Elevated CK-MB of \>10 times upper limit of normal, or cTn (T or I)\>70 times upper limit of normal within 48 hours from the procedure. If cardiac biomarker levels are elevated before the procedure, these levels will be used as the reference instead of normal values.
Time frame: 2 days
Other outcomes of interest
Length of In-hospital stay (number of days)
Time frame: 7 days
Plan to share: No — Investigators do not plan to share individual participant data. However, an overall study data and it's publication results shall be uploaded upon completion of this project at Ct.Gov.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 24 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Translumina GmbH